Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Routbort

Showing results (121-130 of 175) with videos related to

Pageof 18
Sort By:
Haematologica|October 2, 2025
Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitorNicholas J Short, Sanam Loghavi, Musa Yilmaz, et al.
Oncotarget|May 28, 2015
Clinical next generation sequencing to identify actionable aberrations in a phase I programGenevieve M Boland, Sarina A Piha-Paul, Vivek Subbiah, et al.
Haematologica|September 2, 2018
Persistent <i>IDH1/2</i> mutations in remission can predict relapse in patients with acute myeloid leukemiaChi Young Ok, Sanam Loghavi, Dawen Sui, et al.
Journal of Cutaneous Pathology|March 11, 2015
Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutationsDavid L Stockman, Jonathan L Curry, Carlos A Torres-Cabala, et al.
Human Pathology|March 22, 2016
Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patientsMariko Yabe, L Jeffrey Medeiros, Guilin Tang, et al.
JCO Precision Oncology|September 14, 2020
Targeting <i>ERBB2</i> (<i>HER2</i>) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional IndicationsEcaterina E Ileana Dumbrava, Kavitha Balaji, Kanwal Raghav, et al.
Oncotarget|January 27, 2017
Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarrayHui Chen, Rajesh R Singh, Xinyan Lu, et al.
American Journal of Hematology|July 17, 2024
Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemiaSanam Loghavi, Qing Wei, Farhad Ravandi, et al.
Oncotarget|April 19, 2017
A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratoryNatalia Paez Arango, Lauren Brusco, Kenna R Mills Shaw, et al.
Cancer|December 3, 2016
Clinicopathological features and clinical outcomes associated with TP53 and BRAF<sup>N</sup><sup>on-</sup><sup>V</sup><sup>600</sup> mutations in cutaneous melanoma patientsDae Won Kim, Lauren E Haydu, Aron Y Joon, et al.
Pageof 18

Showing results (121-130 of 175) with videos related to

Sort By:
Pageof 18
Haematologica|October 2, 2025
Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitorNicholas J Short, Sanam Loghavi, Musa Yilmaz, et al.
Oncotarget|May 28, 2015
Clinical next generation sequencing to identify actionable aberrations in a phase I programGenevieve M Boland, Sarina A Piha-Paul, Vivek Subbiah, et al.
Haematologica|September 2, 2018
Persistent <i>IDH1/2</i> mutations in remission can predict relapse in patients with acute myeloid leukemiaChi Young Ok, Sanam Loghavi, Dawen Sui, et al.
Journal of Cutaneous Pathology|March 11, 2015
Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutationsDavid L Stockman, Jonathan L Curry, Carlos A Torres-Cabala, et al.
Human Pathology|March 22, 2016
Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patientsMariko Yabe, L Jeffrey Medeiros, Guilin Tang, et al.
JCO Precision Oncology|September 14, 2020
Targeting <i>ERBB2</i> (<i>HER2</i>) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional IndicationsEcaterina E Ileana Dumbrava, Kavitha Balaji, Kanwal Raghav, et al.
Oncotarget|January 27, 2017
Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarrayHui Chen, Rajesh R Singh, Xinyan Lu, et al.
American Journal of Hematology|July 17, 2024
Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemiaSanam Loghavi, Qing Wei, Farhad Ravandi, et al.
Oncotarget|April 19, 2017
A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratoryNatalia Paez Arango, Lauren Brusco, Kenna R Mills Shaw, et al.
Cancer|December 3, 2016
Clinicopathological features and clinical outcomes associated with TP53 and BRAF<sup>N</sup><sup>on-</sup><sup>V</sup><sup>600</sup> mutations in cutaneous melanoma patientsDae Won Kim, Lauren E Haydu, Aron Y Joon, et al.
Pageof 18